Stifel Financial Corp Trims Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Stifel Financial Corp cut its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 10.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 90,055 shares of the medical research company’s stock after selling 10,538 shares during the quarter. Stifel Financial Corp owned approximately 0.18% of Charles River Laboratories International worth $16,624,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of CRL. Versant Capital Management Inc grew its holdings in Charles River Laboratories International by 1,071.4% during the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after buying an additional 150 shares during the last quarter. Pinnacle Bancorp Inc. lifted its position in shares of Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 65 shares in the last quarter. GeoWealth Management LLC boosted its stake in shares of Charles River Laboratories International by 311.5% during the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 190 shares during the last quarter. Pilgrim Partners Asia Pte Ltd purchased a new stake in Charles River Laboratories International during the 4th quarter worth about $48,000. Finally, Tortoise Investment Management LLC raised its stake in Charles River Laboratories International by 77.7% in the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock valued at $49,000 after purchasing an additional 115 shares during the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Charles River Laboratories International

In other news, COO Birgit Girshick bought 1,514 shares of the firm’s stock in a transaction dated Thursday, February 20th. The stock was acquired at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the purchase, the chief operating officer now owns 55,058 shares of the company’s stock, valued at $9,064,198.54. This trade represents a 2.83 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO James C. Foster purchased 6,075 shares of the company’s stock in a transaction that occurred on Thursday, February 20th. The shares were purchased at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the purchase, the chief executive officer now directly owns 183,639 shares in the company, valued at $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 1.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on CRL. JPMorgan Chase & Co. lowered their price target on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a report on Thursday, February 20th. The Goldman Sachs Group cut shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $190.00 to $170.00 in a research note on Friday, March 21st. Redburn Atlantic raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price target on the stock in a research note on Monday, March 3rd. William Blair cut Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. Finally, Mizuho dropped their target price on Charles River Laboratories International from $175.00 to $155.00 and set a “neutral” rating for the company in a research note on Wednesday, April 9th. One research analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $182.00.

Charles River Laboratories International Trading Down 0.9 %

NYSE CRL opened at $114.71 on Friday. The firm has a market capitalization of $5.63 billion, a price-to-earnings ratio of 764.73, a PEG ratio of 4.54 and a beta of 1.45. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $254.15. The company’s 50 day moving average price is $146.73 and its 200 day moving average price is $171.24.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. During the same quarter last year, the firm posted $2.46 EPS. The business’s revenue for the quarter was down 1.1% compared to the same quarter last year. On average, sell-side analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).